Summary:

Acute myelogenous leukemia is the second most common leukemia of childhood. Recent advances in tumor cell biology, risk identification based upon biomarker expression profiles, and the introduction of novel salvage regimen for the treatment of patients who have relapsed post-transplant will be examined in this session.